Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1Breast 1

Conditions

Breast Neoplasms 53Ovarian Neoplasms 4Prostatic Neoplasms 3Neoplasms 3Inflammatory Breast Neoplasms 3HER2-positive Breast Cancer 3Carcinoma, Non-Small-Cell Lung 3Stomach Neoplasms 2Solid Tumor 2Rectal Neoplasms 2Neoplasm Metastasis 2Colonic Neoplasms 2Urinary Bladder Neoplasms 1Solid Cancers 1Patient Preference 1Pancreatic Neoplasms 1Neuroendocrine Tumors 1Neuroblastoma 1Neoplasms, Unknown Primary 1Multiple Endocrine Neoplasia 1Malignant Solid Neoplasm 1Lung Neoplasms 1Locally Advanced Breast Cancer 1Her2-Positive Breast Cancer 1HER2-positive Metastatic Breast Cancer 1HER2-positive Early Breast Cancer 1HER2-Positive Early Breast Cancer 1HER2 Positive Breast Cancer 1Fallopian Tube Neoplasms 1Colorectal Neoplasms 1

Interventions

pertuzumab 1atezolizumab 1Trastuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × HER2-positive Metastatic Breast Cancer × pertuzumab × Clear all
NCT03417544 2026-04-27

Atezolizumab + Pertuzumab + Trastuzumab In CNS Mets In BC

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
19 enrolled 26 charts
BreastCNS

HER2-positive Metastatic Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡